NEW YORK, June 19 - Genomica said Tuesday it had appointed Michael Savage, formerly CEO of Molecular Simulations, to its board of directors.

Savage will replace Arnold Levine, who is joining Genomica's scientific advisory board.

Savage was CEO of Molecular Simulations for eight years before the company was acquired by Pharmacopeia in 1998.

Genomica of Boulder, Colo., develops and markets software products and services, designed to enable pharmaceutical and biotechnology researchers to accelerate the drug discovery and development process.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.